Pharmacoepidemiology and Drug Safety

Papers
(The TQCC of Pharmacoepidemiology and Drug Safety is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Accuracy of Japanese claims data in identifying diabetes‐related complications56
Control yourself: ISPE‐endorsed guidance in the application of self‐controlled study designs in pharmacoepidemiology40
Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators37
Validation of diagnosis codes to identify hospitalized COVID‐19 patients in health care claims data34
QTc prolongation in COVID‐19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta‐analysis30
Core concepts in pharmacoepidemiology: Violations of the positivity assumption in the causal analysis of observational data: Consequences and statistical approaches28
HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real‐world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force27
Safety of Andrographis paniculata: A systematic review and meta‐analysis24
Sodium‐glucose cotransporter‐2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis23
Comparison of drug prescribing before and during the COVID‐19 pandemic: A cross‐national European study23
Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data23
Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID‐19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 322
Core concepts in pharmacoepidemiology: Validation of health outcomes of interest within real‐world healthcare databases22
Polypharmacy and the risk of drug–drug interactions and potentially inappropriate medications in hospital psychiatry21
Real‐world evidence to support regulatory decision making: New or expanded medical product indications21
A COVID‐19‐ready public health surveillance system: The Food and Drug Administration's Sentinel System20
Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study19
Antidepressant use in Australia and Sweden—A cross‐country comparison19
High‐dimensional propensity scores for empirical covariate selection in secondary database studies: Planning, implementation, and reporting18
Utilization of drugs with reports on potential efficacy or harm on COVID‐19 before, during, and after the first pandemic wave18
Bipolar disorder prevalence and psychotropic medication utilisation in Hong Kong and the United Kingdom18
Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population‐based cohort studies17
Validity of claims‐based algorithms to identify neurodevelopmental disorders in children17
Real‐world data: Assessing electronic health records and medical claims data to support regulatory decision‐making for drug and biological products17
Chronic opioid use and complication risks in women with endometriosis: A cohort study in US administrative claims16
Trends in fall‐related mortality and fall risk increasing drugs among older individuals in the United States,1999–201716
Core concepts in pharmacoepidemiology: Measures of drug utilization based on individual‐level drug dispensing data16
Validation of diagnostic coding for interstitial lung diseases in an electronic health record system in Hong Kong16
Use of hydrochlorothiazide and risk of skin cancer in a large nested case‐control study in Spain15
Evaluation of more than one billion outpatient prescriptions and eight‐year trend showing a remarkable reduction in antibiotic prescription in Turkey: A success model of governmental interv15
Incorporating patient generated health data into pharmacoepidemiological research14
Identification of pregnancies and infants within a US commercial healthcare administrative claims database14
Validity of ICD‐10‐CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies14
Validation of an ICD‐10‐based algorithm to identify stillbirth in the Sentinel System14
The Chang Gung Research Database: Multi‐institutional real‐world data source for traditional Chinese medicine in Taiwan14
Using artificial intelligence to identify anti‐hypertensives as possible disease modifying agents in Parkinson's disease13
Risk of myopericarditis following COVID‐19 mRNA vaccination in a large integrated health system: A comparison of completeness and timeliness of two methods13
Validity of congenital malformation diagnoses in healthcare claims from a university hospital in Japan13
Medication‐related problems in older people in Catalonia: A real‐world data study13
Effect of ICD‐9‐CM to ICD‐10‐CM coding system transition on identification of common conditions: An interrupted time series analysis13
New‐user and prevalent‐user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices13
Initial opioid prescription patterns and the risk of ongoing use and adverse outcomes13
Transparency of high‐dimensional propensity score analyses: Guidance for diagnostics and reporting13
Trends in strong opioid prescribing in Ireland: A repeated cross‐sectional analysis of a national pharmacy claims database between 2010 and 201912
Trends in benzodiazepine and alternative hypnotic use in relation with multimorbidity among older adults in Quebec, Canada12
Validation studies of Japanese administrative health care data: A scoping review12
Using administrative healthcare database records to study trends in prescribed medication dispensed during pregnancy in Belgium from 2003 to 201712
Drug exposure misclassification in pharmacoepidemiology: Sources and relative impact12
Identifying prescribing cascades in Alzheimer's disease and related dementias: The calcium channel blocker‐diuretic prescribing cascade12
Multimorbidity measures from health administrative data using ICD system codes: A systematic review11
Validation of an International Classification of Disease, 10th revision coding adaptation for the Charlson Comorbidity Index in United States healthcare claims data11
What are the patients' and health care professionals' understanding and behaviors towards adverse drug reaction reporting and additional monitoring?11
A systematic review of how missing data are handled and reported in multi‐database pharmacoepidemiologic studies11
Generalizability and accuracy of IBM MarketScan health risk assessment instrument data for augmentation of commercial claims data11
Global COVID‐19 pandemic and reporting behavior ‐ An analysis of the Food and Drug Administration adverse events reporting system11
Chronic pain patients' willingness to share personal identifiers on the web for the linkage of medico‐administrative claims and patient‐reported data: The chronic pain treatment cohort11
Performance assessment of different machine learning approaches in predicting diabetic ketoacidosis in adults with type 1 diabetes using electronic health records data11
Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes11
Validation of diagnosis codes in healthcare databases in Taiwan, a literature review11
An investigation on the association between sodium glucose co‐transporter 2 inhibitors use and acute pancreatitis: A VigiBase study10
Visualizations throughout pharmacoepidemiology study planning, implementation, and reporting10
Association between different diabetes medication classes and risk of Parkinson's disease in people with diabetes10
Use of negative controls in a prescription sequence symmetry analysis to reduce time‐varying bias10
Categorization of COVID‐19 severity to determine mortality risk10
A systematic review and meta‐analysis of observational studies of the association between the use of incretin‐based therapies and the risk of pancreatic cancer10
Building an active medical product safety surveillance system in Taiwan: Adaptation of the U.S. Sentinel System common data model structure to the National Health Insurance Research Database in Taiwan10
Effectiveness of risk minimisation measures for valproate: A drug utilisation study in Europe10
Identification of rheumatoid arthritis in German claims data using different algorithms: Validation by cross‐sectional patient‐reported survey data10
Greedy caliper propensity score matching can yield variable estimates of the treatment‐outcome association—A simulation study10
Developing algorithms for identifying major structural birth defects using automated electronic health data10
Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studies9
Postoperative inpatient utilization of opioid and opioid‐sparing analgesics in the United States hospitals, 2007–20179
Differential frequency in imaging‐based outcome measurement: Bias in real‐world oncology comparative‐effectiveness studies9
Using machine learning to identify diabetes patients with canagliflozin prescriptions at high‐risk of lower extremity amputation using real‐world data9
Chronic prescription opioid use in pregnancy in the United States9
Pharmacovigilance network as an additional tool for the surveillance of antimicrobial resistance9
Validity of a model using routinely collected data for identifying infections following gastric, colon, and liver cancer surgeries9
Validity of identification algorithms combining diagnostic codes with other measures for acute ischemic stroke in MID‐NET®9
SGLT‐2 inhibitors and the risk of hospitalization for community‐acquired pneumonia: A population‐based cohort study9
Factors associated with the use of the prescription monitoring program by prescribers and pharmacists in Texas9
Evaluation of the key prescription sequence symmetry analysis assumption using the calcium channel blocker: Loop diuretic prescribing cascade9
Use of negative control outcomes to assess the comparability of patients initiating lipid‐lowering therapies8
COVID‐19 pharmacotherapy utilization patterns during pregnancy: International Registry of Coronavirus Exposure in Pregnancy8
Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults8
Comparison of the incidence of bleeding between baloxavir marboxil and other anti‐influenza drugs among outpatients with influenza virus infection: A retrospective cohort study using an employment‐bas8
Overview of the European post‐authorisation study register post‐authorization studies performed in Europe from September 2010 to December 20188
Hydrochlorothiazide and risk of melanoma subtypes8
IncidencePrevalence: An R package to calculate population‐level incidence rates and prevalence using theOMOPcommon data model8
Inflammatory bowel disease patients provide reliable self‐reported medical information: A multicentre prospective pharmacovigilance monitoring system8
Nonsteroidal anti‐inflammatory drugs associated acute kidney injury in hospitalized children: A systematic review and meta‐analysis8
Use of a mobile app to capture supplemental health information during pregnancy: Implications for clinical research8
Mobile apps for quick adverse drug reaction report: A scoping review8
Association between antidepressant use in pregnancy and gestational diabetes mellitus: Results from the Norwegian Mother, Father and Child Cohort Study8
More extreme duplication in the U.S. FDA FAERS database and a suggested check point for disproportionality analysis8
More extreme duplication in FDA Adverse Event Reporting System detected by literature reference normalization and fuzzy string matching8
Use of hydrochlorothiazide in Denmark following publication of skin cancer risk findings8
Impact of adherence to drugs for secondary prevention on mortality and cardiovascular morbidity: A population‐based cohort study. IMPACT study8
Impact of direct‐acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers8
Sensitivity and specificity in signal detection with the reporting odds ratio and the information component8
Prescribing of menopausal hormone therapy in Germany: Current status and changes between 2004 and 20168
Very high PD‐L1 expression as a prognostic indicator of overall survival among patients with advanced non‐small cell lung cancer receiving anti‐PD‐(L)1 monotherapies i7
Proton pump inhibitors may enhance the risk of citalopram‐ and escitalopram‐associated sudden cardiac death among patients receiving hemodialysis7
Health outcomes coding trends in the US Food and Drug Administration's Sentinel System during transition to International Classification of Diseases‐10 coding system: A brief review7
Prevalence and distribution of high‐risk prescription opioid use in the United States, 2011–20167
Core concepts in pharmacoepidemiology: Fundamentals of the cohort and case–control study designs7
Identifying frequent drug combinations associated with delirium in older adults: Application of association rules method to a case‐time‐control design7
Thromboembolic events after Ad.26.COV2.S COVID‐19 vaccine: Reports to the Vaccine Adverse Event Reporting System7
Methods for drug safety signal detection using routinely collected observational electronic health care data: A systematic review7
Estimation of adverse drug reaction reporting in Iran: Correction for underreporting7
Hepatic adverse drug reactions in Malaysia: An 18‐year review of the national centralized reporting system7
Development and validation of a predictive model algorithm to identify anaphylaxis in adults with type 2 diabetes inU.S.administrative claims data7
Validation of an electronic algorithm for Hodgkin and non‐Hodgkin lymphoma in ICD‐10‐CM7
The utility of real‐world evidence for benefit‐risk assessment, communication, and evaluation of pharmaceuticals: Case studies7
Inventory of real‐world data sources in Japan: Annual survey conducted by the Japanese Society for Pharmacoepidemiology Task Force7
Trends in the use of disease‐modifying therapies among reproductive‐aged women with multiple sclerosis in the United States from 2010 to 20197
Drug product dispensing and estimates of use in a general population survey as a signal detection problem7
Validation to correct for outcome misclassification bias7
Pharmacological and epidemiological considerations while constructing treatment episodes using observational data: A simulation study7
Emulation of a randomized controlled trial in ulcerative colitis with US and French claims data: Infliximab with thiopurines compared to infliximab monotherapy7
Validation of serostatus of rheumatoid arthritis using ICD‐10 codes in administrative claims data6
Emergency hospitalizations for adverse drug events in China: Clinical pharmacists' approach to assessment and categorization6
Using structural topic modelling to reveal patterns in reports on opioid drugs in a pharmacovigilance database6
Evaluating opioid analgesic prescribing limits: A narrative review6
Assessing polypharmacy in the older population: Comparison of a self‐reported and prescription based method6
6
Suitability of databases in the Asia‐Pacific for collaborative monitoring of vaccine safety6
Off‐label drug use in neonates and infants in Spain: A five‐year observational study6
Signals from the Dutch national spontaneous reporting system: Characteristics and regulatory actions6
The role of prenatal exposure to antidepressants, anxiolytic, and hypnotics and its underlying illness on the risk of miscarriage using BIFAP database6
Machine learning for improving high‐dimensional proxy confounder adjustment in healthcare database studies: An overview of the current literature6
Real‐world reproducibility study characterizing patients newly diagnosed with multiple myeloma using Clinical Practice Research Datalink, a UK‐based electronic health records database6
6
Comparative neurological safety of fluoroquinolones versus therapeutic alternatives6
Relation between anticholinergic burden and cognitive impairment: Results from the Monzino 80‐plus population‐based study6
Time‐related biases in perinatal pharmacoepidemiology: A systematic review of observational studies6
Ondansetron use in early pregnancy and the risk of late pregnancy outcomes6
Tell me what you want, what you really really want: Estimands in observational pharmacoepidemiologic comparative effectiveness and safety studies6
Acute kidney injury identification for pharmacoepidemiologic studies: Use of laboratory electronic acute kidney injury alerts versus electronic health records in Hospital Episode Statistics6
International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID‐19 pandemic: A cross‐sectional analysis of 66 countries6
Method used to identify adenomyosis and potentially undiagnosed adenomyosis in a large, U.S. electronic health record database6
A data‐informed approach using individualised dispensing patterns to estimate medicine exposure periods and dose from pharmaceutical claims data6
Validation of claims‐based algorithms to identify non‐live birth outcomes6
Data sources for drug utilization research in Latin American countries—A cross‐national study: DASDUR‐LATAM study6
Glucosamine and lower mortality and cancer incidence: Selection bias in the observational studies6
Development and validation of an electronic health records‐based opioid use disorder algorithm by expert clinical adjudication among patients with prescribed opioids6
Where to begin? Thirty must‐read papers for newcomers to pharmacoepidemiology6
Using Joinpoint regression for drug utilization research: Tutorial and case study of prescription opioid use in the United States6
Effect of concomitant antiplatelet therapy on ischemic and hemorrhagic events in patients taking oral anticoagulants for nonvalvular atrial fibrillation in daily clinical practice6
Predicting obesity and smoking using medication data: A machine‐learning approach6
Antibiotic utilization within 18 community hospitals in the United States: A 5‐year analysis5
Novel methods for pregnancy drug safety surveillance in the FDA Sentinel System5
Evaluating awareness, knowledge and practice of healthcare professionals following implementation of a revised pregnancy prevention programme for isotretinoin in Ireland: A multi‐stakeholder cross‐sec5
Women on diuretics have a higher risk of hospital admission because of hyponatremia than men5
Artificial intelligence in pharmacovigilance: Do we need explainability?5
Association of baloxavir marboxil prescription with subsequent medical resource utilization among school‐aged children with influenza5
Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System5
Effectiveness of risk minimisation measures for valproate: A cross‐sectional survey among physicians in Europe5
Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real‐world trials5
A comparison of confounder selection and adjustment methods for estimating causal effects using large healthcare databases5
Risk of major congenital malformations associated with first‐trimester exposure to propulsives: A health administrative database study in Japan5
Utilization of nonguideline concordant antibiotic treatment following acute otitis media in children in the United States5
Exposure to nitrosatable drugs during pregnancy and childhood cancer: A matched case–control study in Denmark, 1996–20165
Increasing rates of buprenorphine diversion in the United States, 2002 to 20195
Use of preventive drugs during the last year of life in older adults with cancer or chronic progressive diseases5
Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post‐authorization safety cohort study conducted in Europe and in the United States5
Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta‐analysis of random5
Alternative analytic and matching approaches for the prevalent new‐user design: A simulation study5
Validity of hospital ICD‐10‐GM codes to identify anaphylaxis5
Bias of time‐varying exposure effects due to time‐varying covariate measurement strategies5
SARS‐CoV‐2 vaccine‐related adverse events in Zimbabwe: The need to strengthen pharmacovigilance in resource‐limited settings5
“Take up to eight tablets per day”: Incorporating free‐text medication instructions into a transparent and reproducible process for preparing drug exposure data for pharmacoepidemiology5
Validation of international classification of diseases, tenth revision, clinical modification diagnosis codes for heart failure subtypes5
Prediction of post‐vaccination Guillain‐Barré syndrome using data from a passive surveillance system5
Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study5
Risk of delirium associated with antimuscarinics in older adults: A case‐time‐control study5
Investigating drug safety in pregnancy based on the German Pharmacoepidemiological Research Database (GePaRD): A proof‐of‐concept analysis on the association between valproate and spina bifida4
Direct healthcare costs of chronic kidney disease management in Italy: What cost‐savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis‐stimulating agents?4
Perinatal pharmacoepidemiology: How often are key methodological elements reported in publications?4
Real world data to identify target population for new CAR‐T therapies4
Does additional monitoring status increase the reporting of adverse drug reactions? An interrupted time series analysis of EudraVigilance data4
Use of α1‐adrenoceptor antagonists tamsulosin and alfuzosin and the risk of Alzheimer's disease4
A systematic, concept‐based method of developing the exposure measure for drug safety and effectiveness studies4
Comparing LASSO and random forest models for predicting neurological dysfunction among fluoroquinolone users4
Off‐label low dose amitriptyline for insomnia disorder: Patient‐reported outcomes4
Assessing heterogeneity of electronic health‐care databases: A case study of background incidence rates of venous thromboembolism4
Self‐medication practice with antimalarials & the determinants of malaria treatment‐seeking behavior among postpartum mothers in a rural community in Nigeria4
Potentially inappropriate medications in nursing homes and the community older adults using the French health insurance databases4
mRNA COVID‐19 vaccination early in pregnancy and the risk of spontaneous abortion in an international pregnancy registry4
Validation of ICD‐10 hospital discharge diagnosis codes to identify incident and recurrent ischemic stroke from a US integrated healthcare system4
General practitioner prescribing trends among pediatric patients in the United Kingdom: 1998–20184
Association between pre‐admission anticoagulation and in‐hospital death, venous thromboembolism, and major bleeding among hospitalized COVID‐19 patients in Japan4
Telemedicine use among patients with metastatic breast cancer during the COVID‐19 pandemic: Differences by race, age, and region4
Development of a multivariate prediction model to identify individual case safety reports which require clinical review4
Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists4
Use of intravenous iron and risk of anaphylaxis: A multinational observational post‐authorisation safety study in Europe4
Validating a novel algorithm to identify patients with autoimmune hepatitis in an administrative database4
Linkage of public health and all payer claims data for population‐level opioid research4
Intra‐articular and soft‐tissue corticosteroid injections and risk of infections: Population‐based self‐controlled‐risk‐interval design4
Ways COVID‐19 may impact unrelated pharmacoepidemiologic research using routinely collected data4
Population‐based prevalence of polypharmacy and patterns of medication use in southwestern Iran: A cross‐sectional study4
Prescription of antibiotics in the medical care of newly arrived refugees and migrants4
Statin persistence and adherence among older initiators: A nationwide cohort study using the national health insurance claims database in Japan4
Incidence and outcomes of adverse drug reactions to first‐line anti‐tuberculosis drugs and their effects on the quality of life: A multicenter prospective cohort study4
Effectiveness and use of reverse transcriptase polymerase chain reaction point of care testing in a large‐scale COVID‐19 surveillance system4
Validity of claims data for identifying cancer incidence in the Japan public health center‐based prospective study for the next generation4
Potentially inappropriate medication use by level of polypharmacy among US Veterans 49–64 and 65–70 years old4
Prescribed drugs in 27 000 individuals after diagnosis of colorectal cancer: A population‐based cohort study4
The impact of regulatory restrictions on pregabalin use in Saudi Arabia: An interrupted time series analysis4
A review of pregnancy and lactation postmarketing studies required by the FDA4
Role of private prescriptions in the long‐term use of benzodiazepines and Z‐drugs: A patient‐related follow‐up study3
Pragmatic considerations for negative control outcome studies to guide non‐randomized comparative analyses: A narrative review3
3
A comparison of decision and timing of safety related labeling changes for new drugs approved both in Japan and the United States3
Risk of neuropsychiatric adverse events associated with varenicline treatment for smoking cessation among Dutch population: A sequence symmetry analysis3
Trends in use of proton pump inhibitors among adults in the United States from 1999 to 20183
Trends in antipsychotic use for youth with attention‐deficit/hyperactivity disorder and disruptive behavior disorders3
Outpatient insulin‐related adverse events due to mix‐up errors: Findings from two national surveillance systems, United States, 2012–20173
3
High‐throughput screening for prescribing cascades among real world statin initiators3
ABSTRACTS of ICPE 2022, the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Copenhagen, Denmark, 26–28 August, 20223
3
Optimizing therapeutic decision‐making for off‐label medicines use: A scoping review and consensus recommendations for improving practice and research+3
Exploring parity in female authorship of pharmacoepidemiology articles: A case study of the Canadian Network for Observational Drug Effect Studies and its citing articles3
Development and evaluation of a proxy for baseline ECOG PS in advanced non‐small cell lung cancer, bladder cancer, and melanoma: An electronic health record study3
Implementation of risk minimization measures to reduce the risk of tuberculosis among tumor necrosis factor medication users3
Statin use and the risk of progression to vision threatening diabetic retinopathy3
Measured and accounted‐for confounding in pharmacoepidemiologic studies: Some thoughts for practitioners3
Validation of claims‐based algorithms to identify patients with psoriasis3
Observed‐over‐Expected analysis as additional method for pharmacovigilance signal detection in large‐scaled spontaneous adverse event reporting3
Impact of lifestyle and socioeconomic position on use of non‐steroidal anti‐inflammatory drugs: A population‐based cohort study3
Biases associated with epidermal necrolysis reporting in pharmacovigilance: An exploratory analysis using World Health Organization VigiBase3
Medicine use in children aged under 12 years—Population survey in Finland3
The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database3
Antibiotic utilisation in primary and revision total hip replacement patients: A registry linkage cohort study of 106 253 patients using the Australian Orthopaedic Association National Joint Replaceme3
Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time ser3
Validation of diagnostic coding for bronchiectasis in an electronic health record system in Hong Kong3
Selective serotonin reuptake inhibitors, post‐treatment sexual dysfunction and persistent genital arousal disorder: A systematic review3
Risk of antibiotic treatment failure in premenopausal women with uncomplicated urinary tract infection3
3
Association between methylphenidate and risk of myocardial infarction: A multinational self‐controlled case series study3
Proton pump inhibitors long term use‐trends and patterns over 15 years of a large health maintenance organization3
The most common medications dispensed to lactating persons: An electronic health record‐based approach3
Systematic evaluation of the efficacy‐effectiveness gap of systemic treatments in extensive disease small cell lung cancer3
Antibacterial‐associated acute kidney injury among older adults: A post‐marketing surveillance study using the FDA adverse events reporting system3
Management of epilepsy in Lebanon: Medication reviews and drug‐related problems3
The risk of miscarriage after COVID‐19 vaccination before and during pregnancy3
Detecting deviations from the efficacy and safety results of single‐arm trials using real‐world data: The case of a CAR‐T cell therapy in B‐cell lymphoma3
Monitoring real‐life utilization of pembrolizumab in advanced melanoma using the Portuguese National Cancer Registry3
Quality of rheumatoid arthritis recording in United Kingdom Clinical Practice Research Datalink Aurum3
The marked oscillatory pattern in prescription opioid utilization in Canada since 2000: Selected observations and questions for outcomes and policy3
0.42727494239807